top of page

I3LUNG
INTEGRATIVE SCIENCE, INTELLIGENT DATA PLATFORM FOR INDIVIDUALIZED LUNG CANCER CARE WITH IMMUNOTHERAPY

CLINICAL TRIAL DETAILS
I3LUNG IS A EUROPEAN PROJECT FUNDED UNDER THE FRAMEWORK OF THE H2020 CALL "ENSURING ACCESS TO INNOVATIVE, SUSTAINABLE AND HIGH-QUALITY HEALTH CARE". THE PROJECT AIMS TO DEVELOP A MEDICAL DEVICE TO PREDICT IMMUNOTHERAPY EFFICACY FOR NSCLC PATIENTS THROUGH THE INTEGRATION OF MULTISOURCE DATA (REAL WORLD AND MULTI-OMICS DATA) FROM A RETROSPECTIVE AND A PROSPECTIVE PHASE. THE FINAL OBJECTIVE IS THE ESTABLISHMENT OF A WORLDWIDE DATA SHARING AND ELABORATION PLATFORM (DSEP) AND AN INDIVIDUALIZED PATIENT DECISION AID SYSTEM (iPDAS) TO SUPPORT CLINICIANS IN TREATMENT SELECTION.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
LUNG
6
2200
N/A
Spain, Greece, Italy, Israel, USA, Germany
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
-----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
---
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page
